REVIEW ARTICLE E. David Crawford, Thomas W. Flaig;ONCOLOGY Vol. 26 No. 1
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. Future study is needed to define the optimal sequencing and potential combinations of these new agents.
REVIEW ARTICLE Kyle O. Rove, E. David Crawford;ONCOLOGY Vol. 25 No. 14
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
REVIEW ARTICLE Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
CLINICAL QUANDARIES Waseem Khaliq, Ikechukwu Uzoaru, et al; ONCOLOGY Vol. 24 No. 9
Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
SECOND OPINION Elaine T. Lam et al;ONCOLOGY Vol. 25 No. 9
The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass. He underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm.
SECOND OPINION Thomas W. Flaig, Francisco G. La Rosa, et al;ONCOLOGY Vol. 23 No. 2
The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.
The State of Prostate MRI in 2013 Rajan T. Gupta, MD1,
Christopher R. Kauffman, MD1,
Thomas J. Polascik, MD, FACS2,
Samir S. Taneja, MD3,
Andrew B. Rosenkrantz, MD4, April 15, 2013
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
• Improving Harmonious Precision • Targeted Therapy for Cancer: Asking the Right Questions
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.